1 Day
Source:
بوابة الفجر
_1777352244987_250242181.png&w=48&q=75){kind=small}
Source: بوابة الفجر
1 Dayبوابة الفجر
Source: بوابة الفجر
1 DayReady to play
Ready to play
The circulation of the new substance "Milogabalin" in the Egyptian market, which has similar effects to "Gabapentin," raises concerns about its use as an unregulated substitute. There is a call for the Egyptian Food and Drug Authority to include it among the regulated medicines to ensure safety. Experts have warned against the unorganized trading of this substance, especially after the crisis involving the withdrawal of medications like "Librax," which faced difficulties in being recalled due to the lack of identification numbers and clear mechanisms. They are urging the implementation of strict procedures to regulate the pharmaceutical market and protect the medication system from chaos.
Notice: This Is an AI-Generated Summary
Comments (0)